Literature DB >> 32249899

Incidence and prevalence of giant cell arteritis in Ontario, Canada.

Lillian Barra1,2, Janet E Pope1,2, Priscila Pequeno3, Farah E Saxena3, Mary Bell4, Derek Haaland5,6, Jessica Widdifield3,4,7.   

Abstract

OBJECTIVE: To estimate trends in the incidence and prevalence of GCA over time in Canada.
METHODS: We performed a population-based study of Ontario health administrative data using validated case definitions for GCA. Among Ontario residents ≥50 years of age we estimated the annual incidence and prevalence rates between 2000 and 2018. We performed sensitivity analyses using alternative validated case definitions to provide comparative estimates.
RESULTS: Between 2000 and 2018 there was a relatively stable incidence over time with 25 new cases per 100 000 people >50 years of age. Age-standardized incidence rates were significantly higher among females than males [31 cases (95% CI: 29, 34) vs 15 cases (95% CI: 13, 18) per 100 000 in 2000]. Trends in age-standardized incidence rates were stable among females but increased among males over time. Incidence rates were highest among those ≥70 years of age. Standardized prevalence rates increased from 125 (95% CI 121, 129) to 235 (95% CI 231, 239) cases per 100 000 from 2000 to 2018. The age-standardized rates among males rose from 76 (95% CI 72, 81) cases in 2000 to 156 (95% CI 151, 161) cases per 100 000 population in 2018. Between 2000 and 2018, the age-standardized rates among females similarly increased over time, from 167 (95% CI 161, 173) to 304 (95% CI 297, 310) cases per 100 000 population.
CONCLUSION: The incidence and prevalence of GCA in Ontario is similar to that reported in the USA and northern Europe and considerably higher than that reported for southern Europe and non-European populations.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  epidemiology; giant cell arteritis; health administrative data; incidence and prevalence; validation study

Mesh:

Year:  2020        PMID: 32249899     DOI: 10.1093/rheumatology/keaa095

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  4 in total

1.  Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing.

Authors:  Lihi Eder; Ruth Croxford; Aaron M Drucker; Arielle Mendel; Bindee Kuriya; Zahi Touma; Sindhu R Johnson; Richard Cook; Sasha Bernatsky; Nigil Haroon; Jessica Widdifield
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-09-06       Impact factor: 5.178

Review 2.  One Giant Step for Giant Cell Arteritis: Updates in Diagnosis and Treatment.

Authors:  Marc Dinkin; Editha Johnson
Journal:  Curr Treat Options Neurol       Date:  2021-01-16       Impact factor: 3.598

3.  Trend and Geographic Disparities in the Mortality Rates of Primary Systemic Vasculitis in the United States from 1999 to 2019: A Population-Based Study.

Authors:  Alicia Rodriguez-Pla; Jose Rossello-Urgell
Journal:  J Clin Med       Date:  2021-04-18       Impact factor: 4.964

Review 4.  Global epidemiology of vasculitis.

Authors:  Richard A Watts; Gulen Hatemi; Jane C Burns; Aladdin J Mohammad
Journal:  Nat Rev Rheumatol       Date:  2021-12-01       Impact factor: 20.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.